Neurocrine Biosciences (NBIX) Other Operating Expenses (2010 - 2026)

Neurocrine Biosciences' Other Operating Expenses history runs 16 years deep, the most recent figure standing at $28.6 million for Q1 2026.

• Quarterly Other Operating Expenses changed N/A year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $318.1 million (up 46.86% YoY) and the FY2025 annual result came in at $69.5 million, up 49.46% from the prior year.
• Other Operating Expenses was $28.6 million for Q1 2026 at Neurocrine Biosciences, down from $34.6 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $240.6 million in Q2 2025 and bottomed at $6.1 million in Q3 2022.
• A 5-year average of $69.4 million and a median of $21.4 million in 2025 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 3331.03% in 2022, while the deepest fall reached 92.62% in 2022.
• Neurocrine Biosciences' Other Operating Expenses stood at $7.7 million in 2022, then gained by 10.39% to $8.5 million in 2023, then surged by 44.71% to $12.3 million in 2024, then soared by 181.3% to $34.6 million in 2025, then retreated by 17.34% to $28.6 million in 2026.
• Business Quant data shows NBIX's Other Operating Expenses at $28.6 million in Q1 2026, $34.6 million in Q4 2025, and $14.3 million in Q3 2025.